At a glance
ClinicalIndex Comparison RecordN/ACompleted· 28,812 enrolled
Drug / intervention
no interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Project "XCHANGE" Non-Interventional Study
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Nov 13, 2009·Updated Feb 25, 2021
In Brief
An observational study evaluating no intervention for Glaucoma and Ocular Hypertension. Completed, enrolled 28,812 participants.
Detailed Summary
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions. Data were entered into an electronic case report form.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2000
Primary CompletionDec 2008
First PostedNov 2009
TodayJul 2026
First PostedNov 13, 2009
Enrollment StartJan 1, 2000
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 16.6 years ago
Interventions
no interventionother